Abstract:Funding Acknowledgements None. Background Senescent endothelial cells (EC) are key players in the pathophysiology of cardiovascular diseases and characterized by a reduced angiogenic and regenerative potential. Therefore, reversing EC senescence represents a promising therapeutic strategy to restore vascular integrity and increase health and lifespan. Purpose Here, we show a reversal of EC senescence following the application of a pharmacological, non-genetic, partial reprogramming strategy to induce a timely restricted induction of the Yamanaka-factors Oct3/4, Sox2, Klf4 and c-Myc (OSKM). Methods Methods to characterize the effects of pharmacological reprogramming included the quantification of gene expression as well as functional analysis of EC in vitro. In addition, the regenerative capacity of EC was evaluated in a hind-limb ischemia model in vivo in young and old C57BL/6 mice. Results The application of a pharmacological reprogramming cocktail led to a strong but timely restricted activation of the Yamanaka-factors Oct3/4, Sox2, Klf4 and c-Myc in replicative senescent ECs. This activation occurred on both mRNA and protein levels (p<0.0001), concurrently significantly reducing markers of cellular aging as p16ink4a, p14arf, TNFα, IL-1b, IL-6 and CD44 (p<0.01 respectively p<0.0001), while enhancing their cellular function. Pharmacological reprogramming notably augmented the migratory (p<0.001) and proliferative capacities (p<0.01) of the replicate senescence EC and positively influenced their angiogenic functions such as sprouting (p<0.0001) and tube formation (p<0.01). Telomere length was stabilized (p<0.05) and production of reactive oxygen species decreased (p 0.05). Over prolonged periods, the treated ECs maintained consistently low expression of aging markers (p16ink4a and p14arf, p<0.01) while preserving their migratory capabilities (p<0.05). In vivo, a significantly improved blood flow was observed after hind limb ischemia in 22 months old C57BL/6 mice after 7 and 14 days (p<0.001), alongside a significant increase in capillary density in the gastrocnemius muscle quantified by CD31 staining (p 0.05). Conclusion In conclusion, we demonstrate that a short induction of OSKM via a pharmacological approach holds the potential to reverse cellular senescence in EC in vitro with improved regenerative and angiogenic capacities and thus to enhance endothelial regenerative capacity in vivo. This might present a promising strategy for ischemic diseases.

Targeted partial reprogramming of age-associated cell states improves markers of health in mouse models of aging

Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice

In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice

Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells.

In vivo reprogramming of leads to heterogeneous effects on lifespan

Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells

AAV-mediated expression of secreted and transmembrane αKlotho isoforms rescues relevant aging hallmarks in senescent SAMP8 mice

Multi-omics characterization of partial chemical reprogramming reveals evidence of cell rejuvenation

Reprogramming to Alleviate Alzheimer’s Disease Through Ameliorating Microglial Inflammation and Neuronal Damage

Enhancing cellular regeneration through targeted pharmacological reprogramming of senescent endothelial cells

Transplanting rejuvenated blood stem cells extends lifespan of aged immunocompromised mice

Partial Cellular Reprogramming Stably Restores the Stemness of Senescent Epidermal Stem Cells.

Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice

Cognitive rejuvenation in old rats by hippocampal OSKM gene therapy

Senolytics improve physical function and increase lifespan in old age

Chemically induced reprogramming to reverse cellular aging

Genome-wide CRISPR activation screening in senescent cells reveals SOX5 as a driver and therapeutic target of rejuvenation

Reprogramming to recover youthful epigenetic information and restore vision

Slowing cellular senescence

Systemic induction of senescence in young mice after single heterochronic blood exchange

Targeting CK2 eliminates senescent cells and prolongs lifespan in Zmpste24 -deficient mice